Filippo Pietrantonio
Scientific Secretary
About
About
Filippo Pietrantonio works as medical oncologist at National Cancer Institute Fondazione IRCCS of Milan and is responsible for the management of gastric cancer at his Institution. He obtained his medical degree from the University of Parma in 2006. He obtained the specialization in Medical Oncology in 2011 at the University of Milan.
Dr. Pietrantonio’s clinical and research interest mainly relies on gastrointestinal malignancies. In particular, he is involved in the management of patients with colorectal and esophago-gastric cancer. Moreover, he cooperated in the clinical and translational research activity with the aim of developing new therapeutic strategies against these tumors. He has co-authored about 200 publications in international journals and he is full member of Associazione Italiana di Oncologia Medica (AIOM), European Society for Medical Oncology (ESMO) and European Organisation for Research and Treatment of Cancer (EORTC) .
Publications
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study
Future Oncol – 2023 Jul
doi: 10.2217/fon-2023-0406 – PubMed ID: 37577810
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation
J Clin Oncol. 2023 Aug 3
doi: 10.1200/JCO.23.00506 – PubMed ID: 37535876
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
Eur J Cancer. 2023 Aug;
doi: 10.1016/j.ejca.2023.05.001 – PubMed ID: 37301718
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Clin Cancer Res. 2023 Jun 13
doi: 10.1158/1078-0432.CCR-22-3878 – PubMed ID: 37022350
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer. 2023 Apr
doi: 10.1136/jitc-2022-006633 – PubMed ID: 37085190
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
Cancer Med. 2023 Apr
doi: 10.1002/cam4.5699 – PubMed ID: 36880426
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
Br J Cancer. 2023 Mar
doi: 10.1038/s41416-023-02180-7 – PubMed ID: 36759721